Lower GI 2016

HPV associated Anal Cancer is genetically distinct

• Meulendijks et al ( 2015 )

138 anal SCC

•

No. % p53 I/C +

% p53 disruptive mutations

3 yr loco-regional control

3yr OS

HPV+ p16+ 93 10% (9/93)

6 %

82 %

87 %

(1/18)

HPV- p16+ 4

33 % (1/3)

75 %

75 %

HPV- p16- 10 50% (5/10)

80 % (8/10)

15 %

35 %

No difference in T or N stage between HPV+ and HPV - cancers